The US Centers for Medicare and Medicaid Services (CMS) has finalized many new coverage policy decisions and coverage rules taking effect in 2020. Medtech Insight provides a review of what industry can expect this year from the Medicare agency.
The medtech industry can look forward in 2020 to several new policies from the Centers for Medicare and Medicaid Services (CMS) that will expand coverage for their products, but the agency will also set new guardrails for how devices are reimbursed.
Among the changes: more device procedures will be covered in outpatient and ambulatory surgical centers (ASCs) by Medicare and several products will qualify for new technology add-on payments at these...
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
